nodes	percent_of_prediction	percent_of_DWPC	metapath
Formoterol—CYP2A6—Prednisolone—multiple sclerosis	0.179	0.297	CbGbCtD
Formoterol—CYP2D6—Fingolimod—multiple sclerosis	0.136	0.226	CbGbCtD
Formoterol—CYP2A6—Dexamethasone—multiple sclerosis	0.106	0.175	CbGbCtD
Formoterol—CYP2C19—Prednisone—multiple sclerosis	0.0701	0.116	CbGbCtD
Formoterol—CYP2C19—Dexamethasone—multiple sclerosis	0.0438	0.0723	CbGbCtD
Formoterol—CYP2C9—Dexamethasone—multiple sclerosis	0.0364	0.0601	CbGbCtD
Formoterol—CYP2D6—Dexamethasone—multiple sclerosis	0.0333	0.055	CbGbCtD
Formoterol—Isoprenaline—MAPK1—multiple sclerosis	0.00534	1	CrCbGaD
Formoterol—Angioedema—Triamcinolone—multiple sclerosis	0.000407	0.00112	CcSEcCtD
Formoterol—Angioedema—Methylprednisolone—multiple sclerosis	0.000406	0.00112	CcSEcCtD
Formoterol—Malaise—Triamcinolone—multiple sclerosis	0.000402	0.00111	CcSEcCtD
Formoterol—Malaise—Methylprednisolone—multiple sclerosis	0.000401	0.0011	CcSEcCtD
Formoterol—Connective tissue disorder—Prednisone—multiple sclerosis	0.000398	0.00109	CcSEcCtD
Formoterol—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000397	0.00109	CcSEcCtD
Formoterol—Oedema—Prednisolone—multiple sclerosis	0.000396	0.00109	CcSEcCtD
Formoterol—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000396	0.00109	CcSEcCtD
Formoterol—Dizziness—Azathioprine—multiple sclerosis	0.000394	0.00108	CcSEcCtD
Formoterol—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000394	0.00108	CcSEcCtD
Formoterol—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000393	0.00108	CcSEcCtD
Formoterol—Cough—Triamcinolone—multiple sclerosis	0.000389	0.00107	CcSEcCtD
Formoterol—Tachycardia—Prednisolone—multiple sclerosis	0.000386	0.00106	CcSEcCtD
Formoterol—Hypertension—Triamcinolone—multiple sclerosis	0.000385	0.00106	CcSEcCtD
Formoterol—Hypertension—Methylprednisolone—multiple sclerosis	0.000384	0.00106	CcSEcCtD
Formoterol—Urticaria—Mitoxantrone—multiple sclerosis	0.000383	0.00105	CcSEcCtD
Formoterol—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000381	0.00105	CcSEcCtD
Formoterol—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000381	0.00105	CcSEcCtD
Formoterol—Myalgia—Triamcinolone—multiple sclerosis	0.00038	0.00104	CcSEcCtD
Formoterol—Vomiting—Azathioprine—multiple sclerosis	0.000379	0.00104	CcSEcCtD
Formoterol—Arthralgia—Methylprednisolone—multiple sclerosis	0.000379	0.00104	CcSEcCtD
Formoterol—Myalgia—Methylprednisolone—multiple sclerosis	0.000379	0.00104	CcSEcCtD
Formoterol—Anxiety—Methylprednisolone—multiple sclerosis	0.000377	0.00104	CcSEcCtD
Formoterol—Rash—Azathioprine—multiple sclerosis	0.000376	0.00103	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000376	0.00103	CcSEcCtD
Formoterol—Dermatitis—Azathioprine—multiple sclerosis	0.000376	0.00103	CcSEcCtD
Formoterol—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000375	0.00103	CcSEcCtD
Formoterol—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000375	0.00103	CcSEcCtD
Formoterol—Discomfort—Triamcinolone—multiple sclerosis	0.000375	0.00103	CcSEcCtD
Formoterol—Discomfort—Methylprednisolone—multiple sclerosis	0.000374	0.00103	CcSEcCtD
Formoterol—Headache—Azathioprine—multiple sclerosis	0.000374	0.00103	CcSEcCtD
Formoterol—Dry mouth—Triamcinolone—multiple sclerosis	0.000371	0.00102	CcSEcCtD
Formoterol—Angioedema—Betamethasone—multiple sclerosis	0.00037	0.00102	CcSEcCtD
Formoterol—Angioedema—Dexamethasone—multiple sclerosis	0.00037	0.00102	CcSEcCtD
Formoterol—Conjunctivitis—Methotrexate—multiple sclerosis	0.000366	0.00101	CcSEcCtD
Formoterol—Immune system disorder—Prednisone—multiple sclerosis	0.000365	0.00101	CcSEcCtD
Formoterol—Malaise—Dexamethasone—multiple sclerosis	0.000365	0.001	CcSEcCtD
Formoterol—Malaise—Betamethasone—multiple sclerosis	0.000365	0.001	CcSEcCtD
Formoterol—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000364	0.001	CcSEcCtD
Formoterol—Oedema—Triamcinolone—multiple sclerosis	0.000364	0.001	CcSEcCtD
Formoterol—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000363	0.000998	CcSEcCtD
Formoterol—Arrhythmia—Prednisone—multiple sclerosis	0.000361	0.000994	CcSEcCtD
Formoterol—Infection—Triamcinolone—multiple sclerosis	0.000361	0.000994	CcSEcCtD
Formoterol—Infection—Methylprednisolone—multiple sclerosis	0.000361	0.000992	CcSEcCtD
Formoterol—Haematuria—Methotrexate—multiple sclerosis	0.000359	0.000988	CcSEcCtD
Formoterol—Insomnia—Prednisolone—multiple sclerosis	0.000358	0.000984	CcSEcCtD
Formoterol—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000356	0.000979	CcSEcCtD
Formoterol—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000355	0.000977	CcSEcCtD
Formoterol—Tachycardia—Triamcinolone—multiple sclerosis	0.000355	0.000976	CcSEcCtD
Formoterol—Mental disorder—Prednisone—multiple sclerosis	0.000355	0.000975	CcSEcCtD
Formoterol—Nausea—Azathioprine—multiple sclerosis	0.000354	0.000974	CcSEcCtD
Formoterol—Tachycardia—Methylprednisolone—multiple sclerosis	0.000354	0.000974	CcSEcCtD
Formoterol—Skin disorder—Methylprednisolone—multiple sclerosis	0.000353	0.00097	CcSEcCtD
Formoterol—Malnutrition—Prednisone—multiple sclerosis	0.000352	0.000969	CcSEcCtD
Formoterol—Hypertension—Betamethasone—multiple sclerosis	0.000349	0.00096	CcSEcCtD
Formoterol—Hypertension—Dexamethasone—multiple sclerosis	0.000349	0.00096	CcSEcCtD
Formoterol—Asthenia—Mitoxantrone—multiple sclerosis	0.000346	0.000951	CcSEcCtD
Formoterol—Myalgia—Betamethasone—multiple sclerosis	0.000344	0.000947	CcSEcCtD
Formoterol—Myalgia—Dexamethasone—multiple sclerosis	0.000344	0.000947	CcSEcCtD
Formoterol—Anxiety—Betamethasone—multiple sclerosis	0.000343	0.000944	CcSEcCtD
Formoterol—Anxiety—Dexamethasone—multiple sclerosis	0.000343	0.000944	CcSEcCtD
Formoterol—Discomfort—Dexamethasone—multiple sclerosis	0.00034	0.000936	CcSEcCtD
Formoterol—Discomfort—Betamethasone—multiple sclerosis	0.00034	0.000936	CcSEcCtD
Formoterol—Hypotension—Methylprednisolone—multiple sclerosis	0.000339	0.000933	CcSEcCtD
Formoterol—Pain—Prednisolone—multiple sclerosis	0.000338	0.00093	CcSEcCtD
Formoterol—Pharyngitis—Methotrexate—multiple sclerosis	0.000336	0.000923	CcSEcCtD
Formoterol—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000334	0.000918	CcSEcCtD
Formoterol—Urethral disorder—Methotrexate—multiple sclerosis	0.000332	0.000912	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000331	0.000912	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000331	0.000909	CcSEcCtD
Formoterol—Oedema—Betamethasone—multiple sclerosis	0.00033	0.000908	CcSEcCtD
Formoterol—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.00033	0.000908	CcSEcCtD
Formoterol—Oedema—Dexamethasone—multiple sclerosis	0.00033	0.000908	CcSEcCtD
Formoterol—Anaphylactic shock—Betamethasone—multiple sclerosis	0.00033	0.000908	CcSEcCtD
Formoterol—Diarrhoea—Mitoxantrone—multiple sclerosis	0.00033	0.000907	CcSEcCtD
Formoterol—Insomnia—Triamcinolone—multiple sclerosis	0.000329	0.000905	CcSEcCtD
Formoterol—Insomnia—Methylprednisolone—multiple sclerosis	0.000328	0.000903	CcSEcCtD
Formoterol—Infection—Betamethasone—multiple sclerosis	0.000328	0.000902	CcSEcCtD
Formoterol—Infection—Dexamethasone—multiple sclerosis	0.000328	0.000902	CcSEcCtD
Formoterol—Ill-defined disorder—Prednisone—multiple sclerosis	0.000327	0.000899	CcSEcCtD
Formoterol—Feeling abnormal—Prednisolone—multiple sclerosis	0.000326	0.000897	CcSEcCtD
Formoterol—Visual impairment—Methotrexate—multiple sclerosis	0.000326	0.000896	CcSEcCtD
Formoterol—Dyspnoea—Triamcinolone—multiple sclerosis	0.000324	0.000892	CcSEcCtD
Formoterol—Nervous system disorder—Betamethasone—multiple sclerosis	0.000324	0.00089	CcSEcCtD
Formoterol—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000324	0.00089	CcSEcCtD
Formoterol—Agitation—Prednisone—multiple sclerosis	0.000324	0.00089	CcSEcCtD
Formoterol—Tachycardia—Betamethasone—multiple sclerosis	0.000322	0.000886	CcSEcCtD
Formoterol—Tachycardia—Dexamethasone—multiple sclerosis	0.000322	0.000886	CcSEcCtD
Formoterol—Angioedema—Prednisone—multiple sclerosis	0.000322	0.000885	CcSEcCtD
Formoterol—Dyspepsia—Triamcinolone—multiple sclerosis	0.00032	0.000881	CcSEcCtD
Formoterol—Dyspepsia—Methylprednisolone—multiple sclerosis	0.00032	0.000879	CcSEcCtD
Formoterol—Malaise—Prednisone—multiple sclerosis	0.000318	0.000874	CcSEcCtD
Formoterol—Urticaria—Prednisolone—multiple sclerosis	0.000314	0.000864	CcSEcCtD
Formoterol—Cardiac disorder—Methotrexate—multiple sclerosis	0.000314	0.000863	CcSEcCtD
Formoterol—Fatigue—Triamcinolone—multiple sclerosis	0.000314	0.000863	CcSEcCtD
Formoterol—Fatigue—Methylprednisolone—multiple sclerosis	0.000313	0.000861	CcSEcCtD
Formoterol—Pain—Triamcinolone—multiple sclerosis	0.000311	0.000856	CcSEcCtD
Formoterol—Hypotension—Betamethasone—multiple sclerosis	0.000308	0.000848	CcSEcCtD
Formoterol—Hypotension—Dexamethasone—multiple sclerosis	0.000308	0.000848	CcSEcCtD
Formoterol—Vomiting—Mitoxantrone—multiple sclerosis	0.000307	0.000843	CcSEcCtD
Formoterol—Immune system disorder—Methotrexate—multiple sclerosis	0.000305	0.00084	CcSEcCtD
Formoterol—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000305	0.000838	CcSEcCtD
Formoterol—Hypertension—Prednisone—multiple sclerosis	0.000304	0.000836	CcSEcCtD
Formoterol—Rash—Mitoxantrone—multiple sclerosis	0.000304	0.000836	CcSEcCtD
Formoterol—Dermatitis—Mitoxantrone—multiple sclerosis	0.000304	0.000835	CcSEcCtD
Formoterol—Headache—Mitoxantrone—multiple sclerosis	0.000302	0.000831	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000301	0.000827	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000301	0.000827	CcSEcCtD
Formoterol—Myalgia—Prednisone—multiple sclerosis	0.0003	0.000825	CcSEcCtD
Formoterol—Arthralgia—Prednisone—multiple sclerosis	0.0003	0.000825	CcSEcCtD
Formoterol—Feeling abnormal—Triamcinolone—multiple sclerosis	0.0003	0.000824	CcSEcCtD
Formoterol—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000299	0.000823	CcSEcCtD
Formoterol—Anxiety—Prednisone—multiple sclerosis	0.000299	0.000822	CcSEcCtD
Formoterol—Insomnia—Betamethasone—multiple sclerosis	0.000299	0.000821	CcSEcCtD
Formoterol—Insomnia—Dexamethasone—multiple sclerosis	0.000299	0.000821	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000298	0.000819	CcSEcCtD
Formoterol—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000297	0.000816	CcSEcCtD
Formoterol—Discomfort—Prednisone—multiple sclerosis	0.000296	0.000815	CcSEcCtD
Formoterol—Mental disorder—Methotrexate—multiple sclerosis	0.000296	0.000815	CcSEcCtD
Formoterol—Malnutrition—Methotrexate—multiple sclerosis	0.000294	0.00081	CcSEcCtD
Formoterol—Hypersensitivity—Prednisolone—multiple sclerosis	0.000291	0.000802	CcSEcCtD
Formoterol—Dyspepsia—Dexamethasone—multiple sclerosis	0.000291	0.000799	CcSEcCtD
Formoterol—Dyspepsia—Betamethasone—multiple sclerosis	0.000291	0.000799	CcSEcCtD
Formoterol—Urticaria—Triamcinolone—multiple sclerosis	0.000289	0.000795	CcSEcCtD
Formoterol—Urticaria—Methylprednisolone—multiple sclerosis	0.000288	0.000793	CcSEcCtD
Formoterol—Dysgeusia—Methotrexate—multiple sclerosis	0.000288	0.000793	CcSEcCtD
Formoterol—Body temperature increased—Triamcinolone—multiple sclerosis	0.000288	0.000791	CcSEcCtD
Formoterol—Anaphylactic shock—Prednisone—multiple sclerosis	0.000287	0.000791	CcSEcCtD
Formoterol—Oedema—Prednisone—multiple sclerosis	0.000287	0.000791	CcSEcCtD
Formoterol—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000287	0.000789	CcSEcCtD
Formoterol—Nausea—Mitoxantrone—multiple sclerosis	0.000286	0.000788	CcSEcCtD
Formoterol—Infection—Prednisone—multiple sclerosis	0.000286	0.000785	CcSEcCtD
Formoterol—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000285	0.000784	CcSEcCtD
Formoterol—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000285	0.000784	CcSEcCtD
Formoterol—Back pain—Methotrexate—multiple sclerosis	0.000285	0.000783	CcSEcCtD
Formoterol—Fatigue—Betamethasone—multiple sclerosis	0.000285	0.000783	CcSEcCtD
Formoterol—Fatigue—Dexamethasone—multiple sclerosis	0.000285	0.000783	CcSEcCtD
Formoterol—Pain—Betamethasone—multiple sclerosis	0.000282	0.000776	CcSEcCtD
Formoterol—Pain—Dexamethasone—multiple sclerosis	0.000282	0.000776	CcSEcCtD
Formoterol—Nervous system disorder—Prednisone—multiple sclerosis	0.000282	0.000775	CcSEcCtD
Formoterol—Tachycardia—Prednisone—multiple sclerosis	0.000281	0.000772	CcSEcCtD
Formoterol—Skin disorder—Prednisone—multiple sclerosis	0.000279	0.000768	CcSEcCtD
Formoterol—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000273	0.000751	CcSEcCtD
Formoterol—Feeling abnormal—Betamethasone—multiple sclerosis	0.000272	0.000748	CcSEcCtD
Formoterol—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000272	0.000748	CcSEcCtD
Formoterol—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.00027	0.000742	CcSEcCtD
Formoterol—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.00027	0.000742	CcSEcCtD
Formoterol—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000268	0.000737	CcSEcCtD
Formoterol—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000267	0.000735	CcSEcCtD
Formoterol—Malaise—Methotrexate—multiple sclerosis	0.000265	0.00073	CcSEcCtD
Formoterol—Urticaria—Dexamethasone—multiple sclerosis	0.000262	0.000721	CcSEcCtD
Formoterol—Urticaria—Betamethasone—multiple sclerosis	0.000262	0.000721	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000262	0.00072	CcSEcCtD
Formoterol—Dizziness—Prednisolone—multiple sclerosis	0.000262	0.000719	CcSEcCtD
Formoterol—Asthenia—Triamcinolone—multiple sclerosis	0.000261	0.000718	CcSEcCtD
Formoterol—Abdominal pain—Dexamethasone—multiple sclerosis	0.000261	0.000718	CcSEcCtD
Formoterol—Abdominal pain—Betamethasone—multiple sclerosis	0.000261	0.000718	CcSEcCtD
Formoterol—Body temperature increased—Dexamethasone—multiple sclerosis	0.000261	0.000718	CcSEcCtD
Formoterol—Body temperature increased—Betamethasone—multiple sclerosis	0.000261	0.000718	CcSEcCtD
Formoterol—Asthenia—Methylprednisolone—multiple sclerosis	0.00026	0.000716	CcSEcCtD
Formoterol—Insomnia—Prednisone—multiple sclerosis	0.00026	0.000715	CcSEcCtD
Formoterol—Pruritus—Triamcinolone—multiple sclerosis	0.000257	0.000708	CcSEcCtD
Formoterol—Cough—Methotrexate—multiple sclerosis	0.000257	0.000706	CcSEcCtD
Formoterol—Pruritus—Methylprednisolone—multiple sclerosis	0.000257	0.000706	CcSEcCtD
Formoterol—Dyspepsia—Prednisone—multiple sclerosis	0.000253	0.000696	CcSEcCtD
Formoterol—Myalgia—Methotrexate—multiple sclerosis	0.000251	0.000689	CcSEcCtD
Formoterol—Chest pain—Methotrexate—multiple sclerosis	0.000251	0.000689	CcSEcCtD
Formoterol—Arthralgia—Methotrexate—multiple sclerosis	0.000251	0.000689	CcSEcCtD
Formoterol—Rash—Prednisolone—multiple sclerosis	0.000249	0.000686	CcSEcCtD
Formoterol—Dermatitis—Prednisolone—multiple sclerosis	0.000249	0.000685	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000249	0.000684	CcSEcCtD
Formoterol—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000248	0.000683	CcSEcCtD
Formoterol—Fatigue—Prednisone—multiple sclerosis	0.000248	0.000682	CcSEcCtD
Formoterol—Headache—Prednisolone—multiple sclerosis	0.000248	0.000682	CcSEcCtD
Formoterol—Discomfort—Methotrexate—multiple sclerosis	0.000248	0.000681	CcSEcCtD
Formoterol—Constipation—Prednisone—multiple sclerosis	0.000246	0.000676	CcSEcCtD
Formoterol—Dizziness—Triamcinolone—multiple sclerosis	0.000241	0.000662	CcSEcCtD
Formoterol—Anaphylactic shock—Methotrexate—multiple sclerosis	0.00024	0.000661	CcSEcCtD
Formoterol—Dizziness—Methylprednisolone—multiple sclerosis	0.00024	0.00066	CcSEcCtD
Formoterol—Infection—Methotrexate—multiple sclerosis	0.000239	0.000656	CcSEcCtD
Formoterol—Feeling abnormal—Prednisone—multiple sclerosis	0.000237	0.000651	CcSEcCtD
Formoterol—Asthenia—Dexamethasone—multiple sclerosis	0.000237	0.000651	CcSEcCtD
Formoterol—Asthenia—Betamethasone—multiple sclerosis	0.000237	0.000651	CcSEcCtD
Formoterol—Nervous system disorder—Methotrexate—multiple sclerosis	0.000236	0.000648	CcSEcCtD
Formoterol—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000235	0.000646	CcSEcCtD
Formoterol—Nausea—Prednisolone—multiple sclerosis	0.000235	0.000646	CcSEcCtD
Formoterol—Pruritus—Betamethasone—multiple sclerosis	0.000234	0.000642	CcSEcCtD
Formoterol—Pruritus—Dexamethasone—multiple sclerosis	0.000234	0.000642	CcSEcCtD
Formoterol—Skin disorder—Methotrexate—multiple sclerosis	0.000233	0.000642	CcSEcCtD
Formoterol—Vomiting—Triamcinolone—multiple sclerosis	0.000231	0.000636	CcSEcCtD
Formoterol—Vomiting—Methylprednisolone—multiple sclerosis	0.000231	0.000635	CcSEcCtD
Formoterol—Rash—Triamcinolone—multiple sclerosis	0.000229	0.000631	CcSEcCtD
Formoterol—Dermatitis—Triamcinolone—multiple sclerosis	0.000229	0.00063	CcSEcCtD
Formoterol—Rash—Methylprednisolone—multiple sclerosis	0.000229	0.000629	CcSEcCtD
Formoterol—Dermatitis—Methylprednisolone—multiple sclerosis	0.000229	0.000629	CcSEcCtD
Formoterol—Urticaria—Prednisone—multiple sclerosis	0.000228	0.000628	CcSEcCtD
Formoterol—Headache—Triamcinolone—multiple sclerosis	0.000228	0.000627	CcSEcCtD
Formoterol—Headache—Methylprednisolone—multiple sclerosis	0.000227	0.000625	CcSEcCtD
Formoterol—Abdominal pain—Prednisone—multiple sclerosis	0.000227	0.000625	CcSEcCtD
Formoterol—Body temperature increased—Prednisone—multiple sclerosis	0.000227	0.000625	CcSEcCtD
Formoterol—Diarrhoea—Betamethasone—multiple sclerosis	0.000226	0.000621	CcSEcCtD
Formoterol—Diarrhoea—Dexamethasone—multiple sclerosis	0.000226	0.000621	CcSEcCtD
Formoterol—Hypotension—Methotrexate—multiple sclerosis	0.000225	0.000617	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000219	0.000602	CcSEcCtD
Formoterol—Dizziness—Betamethasone—multiple sclerosis	0.000218	0.0006	CcSEcCtD
Formoterol—Dizziness—Dexamethasone—multiple sclerosis	0.000218	0.0006	CcSEcCtD
Formoterol—Insomnia—Methotrexate—multiple sclerosis	0.000217	0.000598	CcSEcCtD
Formoterol—Nausea—Triamcinolone—multiple sclerosis	0.000216	0.000594	CcSEcCtD
Formoterol—Nausea—Methylprednisolone—multiple sclerosis	0.000216	0.000593	CcSEcCtD
Formoterol—Dyspnoea—Methotrexate—multiple sclerosis	0.000214	0.000589	CcSEcCtD
Formoterol—Somnolence—Methotrexate—multiple sclerosis	0.000214	0.000587	CcSEcCtD
Formoterol—Hypersensitivity—Prednisone—multiple sclerosis	0.000212	0.000582	CcSEcCtD
Formoterol—Dyspepsia—Methotrexate—multiple sclerosis	0.000211	0.000582	CcSEcCtD
Formoterol—Vomiting—Betamethasone—multiple sclerosis	0.00021	0.000577	CcSEcCtD
Formoterol—Vomiting—Dexamethasone—multiple sclerosis	0.00021	0.000577	CcSEcCtD
Formoterol—Rash—Betamethasone—multiple sclerosis	0.000208	0.000572	CcSEcCtD
Formoterol—Rash—Dexamethasone—multiple sclerosis	0.000208	0.000572	CcSEcCtD
Formoterol—Dermatitis—Betamethasone—multiple sclerosis	0.000208	0.000572	CcSEcCtD
Formoterol—Dermatitis—Dexamethasone—multiple sclerosis	0.000208	0.000572	CcSEcCtD
Formoterol—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000207	0.00057	CcSEcCtD
Formoterol—Fatigue—Methotrexate—multiple sclerosis	0.000207	0.00057	CcSEcCtD
Formoterol—Headache—Dexamethasone—multiple sclerosis	0.000207	0.000569	CcSEcCtD
Formoterol—Headache—Betamethasone—multiple sclerosis	0.000207	0.000569	CcSEcCtD
Formoterol—Asthenia—Prednisone—multiple sclerosis	0.000206	0.000567	CcSEcCtD
Formoterol—Pain—Methotrexate—multiple sclerosis	0.000205	0.000565	CcSEcCtD
Formoterol—Pruritus—Prednisone—multiple sclerosis	0.000203	0.000559	CcSEcCtD
Formoterol—Feeling abnormal—Methotrexate—multiple sclerosis	0.000198	0.000544	CcSEcCtD
Formoterol—Diarrhoea—Prednisone—multiple sclerosis	0.000197	0.000541	CcSEcCtD
Formoterol—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000196	0.00054	CcSEcCtD
Formoterol—Nausea—Dexamethasone—multiple sclerosis	0.000196	0.000539	CcSEcCtD
Formoterol—Nausea—Betamethasone—multiple sclerosis	0.000196	0.000539	CcSEcCtD
Formoterol—Urticaria—Methotrexate—multiple sclerosis	0.000191	0.000525	CcSEcCtD
Formoterol—Dizziness—Prednisone—multiple sclerosis	0.00019	0.000523	CcSEcCtD
Formoterol—Body temperature increased—Methotrexate—multiple sclerosis	0.00019	0.000522	CcSEcCtD
Formoterol—Abdominal pain—Methotrexate—multiple sclerosis	0.00019	0.000522	CcSEcCtD
Formoterol—Vomiting—Prednisone—multiple sclerosis	0.000183	0.000503	CcSEcCtD
Formoterol—Rash—Prednisone—multiple sclerosis	0.000181	0.000498	CcSEcCtD
Formoterol—Dermatitis—Prednisone—multiple sclerosis	0.000181	0.000498	CcSEcCtD
Formoterol—Headache—Prednisone—multiple sclerosis	0.00018	0.000495	CcSEcCtD
Formoterol—Hypersensitivity—Methotrexate—multiple sclerosis	0.000177	0.000487	CcSEcCtD
Formoterol—Asthenia—Methotrexate—multiple sclerosis	0.000172	0.000474	CcSEcCtD
Formoterol—Nausea—Prednisone—multiple sclerosis	0.000171	0.00047	CcSEcCtD
Formoterol—Pruritus—Methotrexate—multiple sclerosis	0.00017	0.000467	CcSEcCtD
Formoterol—Diarrhoea—Methotrexate—multiple sclerosis	0.000164	0.000452	CcSEcCtD
Formoterol—Dizziness—Methotrexate—multiple sclerosis	0.000159	0.000437	CcSEcCtD
Formoterol—Vomiting—Methotrexate—multiple sclerosis	0.000153	0.00042	CcSEcCtD
Formoterol—Rash—Methotrexate—multiple sclerosis	0.000151	0.000417	CcSEcCtD
Formoterol—Dermatitis—Methotrexate—multiple sclerosis	0.000151	0.000416	CcSEcCtD
Formoterol—Headache—Methotrexate—multiple sclerosis	0.000151	0.000414	CcSEcCtD
Formoterol—Nausea—Methotrexate—multiple sclerosis	0.000143	0.000392	CcSEcCtD
Formoterol—ADRB2—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	9.24e-05	0.00356	CbGpPWpGaD
Formoterol—ADRB1—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	9.13e-05	0.00351	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—CCR1—multiple sclerosis	8.99e-05	0.00346	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—CXCL13—multiple sclerosis	8.99e-05	0.00346	CbGpPWpGaD
Formoterol—ADRB2—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	8.93e-05	0.00344	CbGpPWpGaD
Formoterol—ADRB1—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	8.88e-05	0.00342	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—CXCL13—multiple sclerosis	8.79e-05	0.00339	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—CCR1—multiple sclerosis	8.79e-05	0.00339	CbGpPWpGaD
Formoterol—ADRB2—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	8.69e-05	0.00334	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	8.41e-05	0.00324	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	8.23e-05	0.00317	CbGpPWpGaD
Formoterol—ADRB1—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	8.19e-05	0.00315	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	8.1e-05	0.00312	CbGpPWpGaD
Formoterol—ADRB1—G alpha (s) signalling events—POMC—multiple sclerosis	8.04e-05	0.00309	CbGpPWpGaD
Formoterol—ADRB2—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	8.02e-05	0.00309	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	7.92e-05	0.00305	CbGpPWpGaD
Formoterol—ADRB2—G alpha (s) signalling events—POMC—multiple sclerosis	7.86e-05	0.00303	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	7.82e-05	0.00301	CbGpPWpGaD
Formoterol—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.65e-05	0.00295	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	7.65e-05	0.00294	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	7.61e-05	0.00293	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	7.44e-05	0.00286	CbGpPWpGaD
Formoterol—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.04e-05	0.00271	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	7.02e-05	0.0027	CbGpPWpGaD
Formoterol—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.97e-05	0.00269	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—S1PR1—multiple sclerosis	6.89e-05	0.00265	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	6.87e-05	0.00264	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—S1PR1—multiple sclerosis	6.74e-05	0.0026	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—CCL3—multiple sclerosis	6.41e-05	0.00247	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	6.32e-05	0.00243	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—CCL3—multiple sclerosis	6.27e-05	0.00241	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—S1PR1—multiple sclerosis	6.26e-05	0.00241	CbGpPWpGaD
Formoterol—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.2e-05	0.00239	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	6.18e-05	0.00238	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—PTGER4—multiple sclerosis	6.17e-05	0.00237	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—S1PR1—multiple sclerosis	6.12e-05	0.00236	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—PTGER4—multiple sclerosis	6.03e-05	0.00232	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—CXCR3—multiple sclerosis	5.95e-05	0.00229	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—RGS1—multiple sclerosis	5.86e-05	0.00226	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—SRM—multiple sclerosis	5.83e-05	0.00224	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—CXCR3—multiple sclerosis	5.82e-05	0.00224	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—CCR2—multiple sclerosis	5.79e-05	0.00223	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—RGS1—multiple sclerosis	5.73e-05	0.00221	CbGpPWpGaD
Formoterol—ADRB1—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	5.72e-05	0.0022	CbGpPWpGaD
Formoterol—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.7e-05	0.0022	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—CCR2—multiple sclerosis	5.67e-05	0.00218	CbGpPWpGaD
Formoterol—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.65e-05	0.00218	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.62e-05	0.00216	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.62e-05	0.00216	CbGpPWpGaD
Formoterol—ADRB2—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	5.6e-05	0.00215	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—GPR65—multiple sclerosis	5.55e-05	0.00214	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	5.44e-05	0.00209	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—GPR65—multiple sclerosis	5.43e-05	0.00209	CbGpPWpGaD
Formoterol—CYP2A6—Biological oxidations—POMC—multiple sclerosis	5.4e-05	0.00208	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—CNR1—multiple sclerosis	5.35e-05	0.00206	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	5.32e-05	0.00205	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—RGS1—multiple sclerosis	5.32e-05	0.00205	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—CNR1—multiple sclerosis	5.23e-05	0.00201	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—RGS1—multiple sclerosis	5.2e-05	0.002	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.13e-05	0.00197	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.13e-05	0.00197	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—CCR1—multiple sclerosis	5.08e-05	0.00196	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—CXCL13—multiple sclerosis	5.08e-05	0.00196	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—GPR65—multiple sclerosis	5.04e-05	0.00194	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—CCR1—multiple sclerosis	4.97e-05	0.00191	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—CXCL13—multiple sclerosis	4.97e-05	0.00191	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—GPR65—multiple sclerosis	4.93e-05	0.0019	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	4.9e-05	0.00189	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—LINGO1—multiple sclerosis	4.88e-05	0.00188	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—CXCL10—multiple sclerosis	4.81e-05	0.00185	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	4.79e-05	0.00185	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—LINGO1—multiple sclerosis	4.77e-05	0.00184	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—CXCL10—multiple sclerosis	4.71e-05	0.00181	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—CCR1—multiple sclerosis	4.61e-05	0.00178	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—CXCL13—multiple sclerosis	4.61e-05	0.00178	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—CXCL13—multiple sclerosis	4.51e-05	0.00174	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—CCR1—multiple sclerosis	4.51e-05	0.00174	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TAGAP—multiple sclerosis	4.23e-05	0.00163	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—CCL5—multiple sclerosis	4.14e-05	0.0016	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TAGAP—multiple sclerosis	4.14e-05	0.00159	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CYP27B1—multiple sclerosis	4.11e-05	0.00158	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CYP24A1—multiple sclerosis	4.11e-05	0.00158	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—CCL5—multiple sclerosis	4.05e-05	0.00156	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	3.83e-05	0.00147	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—GPC5—multiple sclerosis	3.76e-05	0.00145	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	3.75e-05	0.00144	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	3.75e-05	0.00144	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—CCR5—multiple sclerosis	3.73e-05	0.00144	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—S1PR1—multiple sclerosis	3.7e-05	0.00142	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	3.67e-05	0.00141	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—CCR5—multiple sclerosis	3.65e-05	0.00141	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—S1PR1—multiple sclerosis	3.62e-05	0.00139	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—GPC5—multiple sclerosis	3.6e-05	0.00138	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—SRM—multiple sclerosis	3.55e-05	0.00137	CbGpPWpGaD
Formoterol—CYP2A6—NRF2 pathway—TGFB1—multiple sclerosis	3.55e-05	0.00137	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—GPC5—multiple sclerosis	3.52e-05	0.00135	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—PTGER4—multiple sclerosis	3.48e-05	0.00134	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—PTGER4—multiple sclerosis	3.41e-05	0.00131	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—CXCR3—multiple sclerosis	3.37e-05	0.0013	CbGpPWpGaD
Formoterol—CYP2C19—Biological oxidations—POMC—multiple sclerosis	3.29e-05	0.00127	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—CXCR3—multiple sclerosis	3.29e-05	0.00127	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—CCL3—multiple sclerosis	3.29e-05	0.00127	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—CCR2—multiple sclerosis	3.27e-05	0.00126	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—SRM—multiple sclerosis	3.27e-05	0.00126	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—SRM—multiple sclerosis	3.24e-05	0.00125	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—CCL3—multiple sclerosis	3.22e-05	0.00124	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—CCR2—multiple sclerosis	3.2e-05	0.00123	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—PTGER4—multiple sclerosis	3.16e-05	0.00122	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—RGS1—multiple sclerosis	3.14e-05	0.00121	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—RRM1—multiple sclerosis	3.11e-05	0.0012	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—PTGER4—multiple sclerosis	3.1e-05	0.00119	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—RGS1—multiple sclerosis	3.07e-05	0.00118	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—CXCR3—multiple sclerosis	3.06e-05	0.00118	CbGpPWpGaD
Formoterol—CYP2D6—Biological oxidations—POMC—multiple sclerosis	3.03e-05	0.00117	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—CNR1—multiple sclerosis	3.02e-05	0.00116	CbGpPWpGaD
Formoterol—CYP2C9—Biological oxidations—POMC—multiple sclerosis	3e-05	0.00116	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—CXCR3—multiple sclerosis	2.99e-05	0.00115	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—GPR65—multiple sclerosis	2.98e-05	0.00115	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—CCR2—multiple sclerosis	2.97e-05	0.00114	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—CNR1—multiple sclerosis	2.96e-05	0.00114	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—POMC—multiple sclerosis	2.92e-05	0.00112	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—GPR65—multiple sclerosis	2.91e-05	0.00112	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—CCR2—multiple sclerosis	2.91e-05	0.00112	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—CCL2—multiple sclerosis	2.85e-05	0.0011	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—POMC—multiple sclerosis	2.85e-05	0.0011	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—CCL2—multiple sclerosis	2.79e-05	0.00108	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—CNR1—multiple sclerosis	2.74e-05	0.00106	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CXCL13—multiple sclerosis	2.73e-05	0.00105	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CCR1—multiple sclerosis	2.73e-05	0.00105	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—CXCL10—multiple sclerosis	2.72e-05	0.00105	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—CNR1—multiple sclerosis	2.68e-05	0.00103	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CXCL13—multiple sclerosis	2.67e-05	0.00103	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CCR1—multiple sclerosis	2.67e-05	0.00103	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—CXCL10—multiple sclerosis	2.66e-05	0.00102	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	2.5e-05	0.000964	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	2.5e-05	0.000964	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—CXCL10—multiple sclerosis	2.47e-05	0.000951	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.45e-05	0.000942	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—CXCL10—multiple sclerosis	2.42e-05	0.00093	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—CCL5—multiple sclerosis	2.34e-05	0.000901	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	2.3e-05	0.000887	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	2.3e-05	0.000887	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—CCL5—multiple sclerosis	2.29e-05	0.000882	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GPC5—multiple sclerosis	2.29e-05	0.000882	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	2.28e-05	0.000879	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	2.28e-05	0.000879	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.23e-05	0.000859	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—CCL5—multiple sclerosis	2.13e-05	0.000819	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—CCR5—multiple sclerosis	2.11e-05	0.000812	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GPC5—multiple sclerosis	2.11e-05	0.000811	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GPC5—multiple sclerosis	2.09e-05	0.000804	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—CCL5—multiple sclerosis	2.08e-05	0.000801	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—IL2RA—multiple sclerosis	2.08e-05	0.0008	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—CCR5—multiple sclerosis	2.06e-05	0.000794	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—IL2RA—multiple sclerosis	2.03e-05	0.000783	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CCL3—multiple sclerosis	1.94e-05	0.000748	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—CCR5—multiple sclerosis	1.92e-05	0.000737	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CCL3—multiple sclerosis	1.9e-05	0.000731	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—RRM1—multiple sclerosis	1.9e-05	0.000731	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—IL2RA—multiple sclerosis	1.89e-05	0.000727	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—CCR5—multiple sclerosis	1.87e-05	0.000721	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PTGER4—multiple sclerosis	1.87e-05	0.00072	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—IL2RA—multiple sclerosis	1.85e-05	0.000711	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PGR—multiple sclerosis	1.84e-05	0.000709	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PTGER4—multiple sclerosis	1.83e-05	0.000704	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CXCR3—multiple sclerosis	1.81e-05	0.000695	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PGR—multiple sclerosis	1.8e-05	0.000693	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CD28—multiple sclerosis	1.79e-05	0.000688	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—BCHE—multiple sclerosis	1.79e-05	0.000688	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CXCR3—multiple sclerosis	1.77e-05	0.00068	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CCR2—multiple sclerosis	1.76e-05	0.000676	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CD28—multiple sclerosis	1.75e-05	0.000673	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.75e-05	0.000672	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—RRM1—multiple sclerosis	1.73e-05	0.000666	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CCR2—multiple sclerosis	1.72e-05	0.000661	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—POMC—multiple sclerosis	1.65e-05	0.000635	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CNR1—multiple sclerosis	1.62e-05	0.000624	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—POMC—multiple sclerosis	1.61e-05	0.000621	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CNR1—multiple sclerosis	1.59e-05	0.00061	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—POMC—multiple sclerosis	1.5e-05	0.000576	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.47e-05	0.000567	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—CCL2—multiple sclerosis	1.46e-05	0.000564	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—POMC—multiple sclerosis	1.46e-05	0.000564	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CXCL10—multiple sclerosis	1.46e-05	0.000562	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—CCL2—multiple sclerosis	1.43e-05	0.000552	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CXCL10—multiple sclerosis	1.43e-05	0.00055	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.34e-05	0.000517	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—TYK2—multiple sclerosis	1.33e-05	0.000512	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—TYK2—multiple sclerosis	1.3e-05	0.000501	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CD86—multiple sclerosis	1.28e-05	0.000491	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.26e-05	0.000487	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CCL5—multiple sclerosis	1.26e-05	0.000484	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CD86—multiple sclerosis	1.25e-05	0.000481	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CCL5—multiple sclerosis	1.23e-05	0.000473	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—IL2—multiple sclerosis	1.22e-05	0.000469	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—IL2—multiple sclerosis	1.19e-05	0.000459	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—SPP1—multiple sclerosis	1.16e-05	0.000448	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.15e-05	0.000444	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.15e-05	0.000444	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—SPP1—multiple sclerosis	1.14e-05	0.000438	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CCR5—multiple sclerosis	1.13e-05	0.000436	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IL2RA—multiple sclerosis	1.12e-05	0.000429	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CCR5—multiple sclerosis	1.11e-05	0.000426	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—IL2—multiple sclerosis	1.11e-05	0.000426	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IL2RA—multiple sclerosis	1.09e-05	0.00042	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—BCHE—multiple sclerosis	1.09e-05	0.00042	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—IL2—multiple sclerosis	1.08e-05	0.000417	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—APOE—multiple sclerosis	1.08e-05	0.000414	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.05e-05	0.000405	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—APOE—multiple sclerosis	1.03e-05	0.000396	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—APOE—multiple sclerosis	1.01e-05	0.000388	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—BCHE—multiple sclerosis	1e-05	0.000386	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—BCHE—multiple sclerosis	9.94e-06	0.000383	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CD80—multiple sclerosis	9.31e-06	0.000358	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—POMC—multiple sclerosis	9.24e-06	0.000356	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CD80—multiple sclerosis	9.11e-06	0.000351	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—POMC—multiple sclerosis	8.84e-06	0.00034	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CCL2—multiple sclerosis	8.65e-06	0.000333	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—POMC—multiple sclerosis	8.65e-06	0.000333	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—MAPK1—multiple sclerosis	8.47e-06	0.000326	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CCL2—multiple sclerosis	8.46e-06	0.000326	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—ALB—multiple sclerosis	8.42e-06	0.000324	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—MAPK1—multiple sclerosis	8.28e-06	0.000319	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TYK2—multiple sclerosis	7.86e-06	0.000303	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TYK2—multiple sclerosis	7.69e-06	0.000296	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—APOE—multiple sclerosis	6.56e-06	0.000252	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IL2—multiple sclerosis	6.54e-06	0.000252	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—IL6—multiple sclerosis	6.51e-06	0.00025	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IL2—multiple sclerosis	6.4e-06	0.000246	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—IL6—multiple sclerosis	6.36e-06	0.000245	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MMP9—multiple sclerosis	6.19e-06	0.000238	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MMP9—multiple sclerosis	6.05e-06	0.000233	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—APOE—multiple sclerosis	6.03e-06	0.000232	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—APOE—multiple sclerosis	5.98e-06	0.00023	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—POMC—multiple sclerosis	5.63e-06	0.000217	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—STAT3—multiple sclerosis	5.5e-06	0.000212	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—STAT3—multiple sclerosis	5.38e-06	0.000207	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—POMC—multiple sclerosis	5.18e-06	0.000199	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—POMC—multiple sclerosis	5.14e-06	0.000198	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ALB—multiple sclerosis	5.14e-06	0.000198	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MYC—multiple sclerosis	5.11e-06	0.000197	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TGFB1—multiple sclerosis	5.1e-06	0.000196	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MAPK1—multiple sclerosis	5e-06	0.000193	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MYC—multiple sclerosis	5e-06	0.000193	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TGFB1—multiple sclerosis	4.99e-06	0.000192	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MAPK1—multiple sclerosis	4.89e-06	0.000188	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ALB—multiple sclerosis	4.72e-06	0.000182	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ALB—multiple sclerosis	4.68e-06	0.00018	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IL6—multiple sclerosis	3.84e-06	0.000148	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IL6—multiple sclerosis	3.76e-06	0.000145	CbGpPWpGaD
